UB Paderborn / Katalog / Suche / in CDI

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Rheumatology and therapy., 2023-08, Vol.10 (4), p.901-915

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1732 SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1100-S-1100

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1737 THE EFFECTS OF UPADACITINIB ON ULCERATIVE COLITIS SYMPTOM RESOLUTION AND FATIGUE NORMALIZATION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 UACHIEVE AND U-ACCOMPLISH RESULTS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1102-S-1103

2023

Link zum Volltext

Verfügbarkeit prüfen

P128 Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND open-label extension study

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-227-S-228

2022

Link zum Volltext

Verfügbarkeit prüfen

S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e505-e506

2022

Link zum Volltext

Verfügbarkeit prüfen

Tu1477: UPADACITINIB PROMOTES HISTOLOGIC AND ENDOSCOPIC MUCOSAL HEALING: RESULTS FROM THE UPADACITINIB ULCERATIVE COLITIS PHASE 3 PROGRAM

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-978

2022

Link zum Volltext

Verfügbarkeit prüfen

S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S909-S910

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

Alimentary pharmacology & therapeutics, 2024-02, Vol.59 (3), p.393-408

2024

Link zum Volltext

Verfügbarkeit prüfen

A mobile app for measuring the surface area of a burn in three dimensions: comparison to the Lund and Browder assessment

Journal of burn care & research, 2014-11, Vol.35 (6), p.480-483

2014

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Rheumatic & musculoskeletal diseases open, 2022-03, Vol.8 (1), p.e002110

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

The lancet. Gastroenterology & hepatology, 2023-11, Vol.8 (11), p.976-989

2023

Link zum Volltext

Verfügbarkeit prüfen

Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI)

Neuropsychopharmacology (New York, N.Y.), 2003-02, Vol.28 (2), p.244-252

2003

Link zum Volltext

Verfügbarkeit prüfen

Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats

European neuropsychopharmacology, 2006-12, Vol.16 (8), p.561-571

2006

Link zum Volltext

Verfügbarkeit prüfen

Chemical burn to the eyes

Eplasty, 2011-11, Vol.11, p.ic16

2011

Link zum Volltext

Verfügbarkeit prüfen

Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats

Neuropsychopharmacology (New York, N.Y.), 2003-07, Vol.28 (7), p.1219-1226

2003

Link zum Volltext

Verfügbarkeit prüfen

A shot in the face

Eplasty, 2011-09, Vol.11, p.ic13

2011

Link zum Volltext

Verfügbarkeit prüfen

Topics in burn critical care-chest pain

Eplasty, 2013-03, Vol.13, p.ic38

2013

Link zum Volltext

Verfügbarkeit prüfen

Imaging of brain serotonergic neurotransmission involving phospholipase A2 activation and arachidonic acid release in unanesthetized rats

Brain research. Brain research protocols, 2003-08, Vol.12 (1), p.16-25

2003

Link zum Volltext

Verfügbarkeit prüfen

Imaging of brain serotonergic neurotransmission involving phospholipase A 2 activation and arachidonic acid release in unanesthetized rats

Brain research. Brain research protocols, 2003, Vol.12 (1), p.16-25

2003

Link zum Volltext

Verfügbarkeit prüfen

Chemical burn to the eyes

Eplasty, 2011, Vol.11, p.ic16-ic16

2011

Link zum Volltext

Verfügbarkeit prüfen

A shot in the face

Eplasty, 2011, Vol.11, p.ic13-ic13

2011

Link zum Volltext

Verfügbarkeit prüfen

Topics in burn critical care-chest pain

Eplasty, 2013, Vol.13, p.ic38-ic38

2013

Link zum Volltext

Verfügbarkeit prüfen

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Diabetes care, 2010-06, Vol.33 (6), p.1173-1175

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of exenatideand lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Diabetes care, 2010-06, Vol.33 (6), p.1173

2010

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Tu1732 SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Tu1737 THE EFFECTS OF UPADACITINIB ON ULCERATIVE COLITIS SYMPTOM RESOLUTION AND FATIGUE NORMALIZATION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 UACHIEVE AND U-ACCOMPLISH RESULTS

P128 Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND open-label extension study

966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials

Tu1477: UPADACITINIB PROMOTES HISTOLOGIC AND ENDOSCOPIC MUCOSAL HEALING: RESULTS FROM THE UPADACITINIB ULCERATIVE COLITIS PHASE 3 PROGRAM

S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis

A mobile app for measuring the surface area of a burn in three dimensions: comparison to the Lund and Browder assessment

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study

Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI)

Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats

Chemical burn to the eyes

Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats

A shot in the face

Topics in burn critical care-chest pain

Imaging of brain serotonergic neurotransmission involving phospholipase A2 activation and arachidonic acid release in unanesthetized rats

Imaging of brain serotonergic neurotransmission involving phospholipase A 2 activation and arachidonic acid release in unanesthetized rats

Chemical burn to the eyes

A shot in the face

Topics in burn critical care-chest pain

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Effects of exenatideand lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Suchergebnisse filtern